| Literature DB >> 27867425 |
Kaspar Haume1, Soraia Rosa2, Sophie Grellet3, Małgorzata A Śmiałek4, Karl T Butterworth2, Andrey V Solov'yov5, Kevin M Prise2, Jon Golding3, Nigel J Mason1.
Abstract
Radiotherapy is currently used in around 50% of cancer treatments and relies on the deposition of energy directly into tumour tissue. Although it is generally effective, some of the deposited energy can adversely affect healthy tissue outside the tumour volume, especially in the case of photon radiation (gamma and X-rays). Improved radiotherapy outcomes can be achieved by employing ion beams due to the characteristic energy deposition curve which culminates in a localised, high radiation dose (in form of a Bragg peak). In addition to ion radiotherapy, novel sensitisers, such as nanoparticles, have shown to locally increase the damaging effect of both photon and ion radiation, when both are applied to the tumour area. Amongst the available nanoparticle systems, gold nanoparticles have become particularly popular due to several advantages: biocompatibility, well-established methods for synthesis in a wide range of sizes, and the possibility of coating of their surface with a large number of different molecules to provide partial control of, for example, surface charge or interaction with serum proteins. This gives a full range of options for design parameter combinations, in which the optimal choice is not always clear, partially due to a lack of understanding of many processes that take place upon irradiation of such complicated systems. In this review, we summarise the mechanisms of action of radiation therapy with photons and ions in the presence and absence of nanoparticles, as well as the influence of some of the core and coating design parameters of nanoparticles on their radiosensitisation capabilities.Entities:
Keywords: Gold nanoparticles; Nanomedicine; Radiosensitisation
Year: 2016 PMID: 27867425 PMCID: PMC5095165 DOI: 10.1186/s12645-016-0021-x
Source DB: PubMed Journal: Cancer Nanotechnol ISSN: 1868-6958
Fig. 1Illustration of mechanisms of radiation damage. Both photon and ion radiation (red wiggly and straight lines, respectively) may directly damage DNA (marked with yellow stars) or other parts of the cell, such as mitochondria (damage not shown), as well as ionise the medium thereby producing radicals and other reactive species (represented here by the OH radical) as well as secondary electrons, which can cause indirect damage after diffusion (red stars). Secondary electrons may also react with the medium to further increase the number of radicals. See text for further details
Fig. 2Illustration of mechanisms of radiation damage in the presence of nanoparticles. In addition to the direct and indirect damage (yellow and red stars, respectively) to DNA or other parts of the cell (a), the incident radiation may also interact with NPs (b) (illustrated by dashed, wiggly arrows) and induce the emission of secondary electrons which can then react with the medium to increase the production of radicals and other reactive species (like OH radicals); secondary electrons produced by the radiation or by NPs may also induce further electron emission from NPs. c All the secondary species may diffuse and damage other parts of the cell (like mitochondria). See text for further details
Fig. 3Illustration of PEG-coated AuNPs. Output from simulation of 1.4 nm AuNPs coated with a 32 and b 60 PEG molecules. Details in Ref. Haume et al. (2016)
In vitro toxicology studies of cancer models to AuNP exposure for AuNPs smaller than 4 nm
| Size (nm) | Coating | Cancer cell line | Exposure | Time (h) | Toxicity | Ref. |
|---|---|---|---|---|---|---|
| 2 | MMPC1 | COS-1 | 0.38–3 μM | 1–24 | IC50 = 1.0 μM |
Goodman et al. ( |
| MMPC2 | IC50 > 7.37 μM | |||||
| MMPC1 | Red blood cells | 0.27–833 μM | IC50 = 1.1 μM | |||
| MMPC2 | IC50 = 72 μM | |||||
| 3.5 ± 0.7 | Lysine, poly(lysine) | RAW 264.7 mouse macrophage | 10–100 μM | 24–72 | >100 μM after 24 h |
Shukla et al. ( |
| 1.4 | PH2PC6H4SO3H | MV3, | <0.4 mM | 24 | IC50 = 0.24 μM |
Tsoli et al. ( |
| BLM | IC50 = 0.30 μM | |||||
| 1.1 | GSH | HeLa | 5.6 mM | 48 | IC50 = 3130 μM |
Pan et al. ( |
| 1.4 | TPPMS | IC50 = 48 μM | ||||
| TPPMS, GSH | IC50 = 181 μM | |||||
| 1.4 | TPPMS | HeLa | Up to 10 mM | 36 | IC50 = 30 μM |
Pan et al. ( |
| SK-mel-28 | J774A1 IC50 = 30 μM | |||||
| L929 IC50 = 56 μM | ||||||
| TPPTS | HeLa | IC50 = 46 μM | ||||
| 1.9 | BAECs | 0.125-1 mM | ~30% cell death at 1 mM AuNPs exposure |
Rahman et al. ( | ||
| 1.9 | Du-145 | Up to 2 mg/ml | 24 | LD50 = 20 μM |
Coulter et al. ( | |
| MDA-MB-231 | LD50 = 24.6 μM | |||||
| L132 | LD50 = 320 μM |
MMPC1 and MMPC2 mixed monolayer gold clusters functionalised with quarternary ammonium and with carboxylic acid, respectively, TPPMS sodium triphenylphosphine monosulfonate, TPPTS sodium triphenylphosphine trisulfonate, PEG polyethylene glycol, GHS glutathione
In vitro toxicology studies of cancer models to AuNP exposure for AuNPs larger than 4 nm
| Size (nm) | Coating | Cancer cell line | Exposure | Time (h) | Toxicity | Ref. | |
|---|---|---|---|---|---|---|---|
| 4, 12, 18 | CTAB, citrate, cysteine, glucose, biotin | K562 leukaemia | Human | 1–250 nM | 72 | >25 μM |
Connor et al. ( |
| 4.8 | PEG | HeLa | 1–250 μM | 48 | IC50 = 0.205 mM |
Zhang et al. ( | |
| 12.1 | IC50 = 0.477 mM | ||||||
| 27.3 | IC50 = 0.448 mM | ||||||
| 46.4 | IC50 = 0.613 mM | ||||||
| 33 | CTAB, citrate | A549 | 0–120 nM | 48 | IC50 |
Patra et al. ( | |
| BHK21 | No toxicity observed for BHK21 up to these concentrations | ||||||
| 35.6 ± 6.7 | Cetuximab antibody | Panc-1 | 100 nM | IC50 |
Glazer et al. ( | ||
| Cama-1 | NA | ||||||
CTAB cetyltrimethylammonium bromide, PEG polyethylene glycol